Yakup Ergün/X
Nov 10, 2024, 15:41
Yakup Ergün: The era of anthracycline-based chemotherapy in early breast cancer is fading
A recent paper by Thomas Grinda, Clinical Research Fellow at Dana-Farber Cancer Institute, was mentioned by Yakup Ergün, Medical Oncologist at Bower Hospital, on X:
“Anthracyclines in Early Breast Cancer: The Long Goodbye.
The era of anthracycline-based chemotherapy in early breast cancer is fading, with newer treatments offering safer and more effective options for many patients.”
“Anthracyclines in Early Breast Cancer: The Long Goodbye”
Authors: Thomas Grinda, Harold Burstein.
More posts featuring Yakup Ergün.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 12, 2024, 18:20
Nov 12, 2024, 18:17
Nov 12, 2024, 18:13
Nov 12, 2024, 18:08
Nov 12, 2024, 18:06
Nov 12, 2024, 18:05
Nov 12, 2024, 18:01
Nov 12, 2024, 17:54
Nov 12, 2024, 17:52
Nov 12, 2024, 17:51
Nov 12, 2024, 17:20